A one year extension study to CZOL446H2337, multi-center, to evaluate safety and efficacy of zoledronic acid given to all patients every six months in children with weakened bone treated with steroids

Update Il y a 4 ans
Reference: EUCTR2010-020399-41

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To demonstrate that zoledronic acid given long-term, over an additional 12 months from the Core study (CZOL446H2337), is safe for the treatment of osteoporotic children treated with glucocorticoids.


Inclusion criteria

  • Treatment of osteoporosis in a paediatric population (aged 5 to 19 years old) treated with systemic glucocorticoids (i.v. or oral)

Links